Guide to Prescribing Dupixent (dupilumab)
A comprehensive guide on how to prescribe Dupixent on the Pharmaceutical Benefits Scheme, including important information on selecting the appropriate dose, PBS item codes and forms, and easy-to-use checklists for new, switching, or patients continuing on therapy.
PBS Information:
Refer to PBS schedule for full authority information. Authority required for patients aged ≥12 years with chronic severe atopic dermatitis and uncontrolled severe asthma. This product is not listed on the PBS for infants aged 6 months to 5 years with severe atopic dermatitis; children 6 to 11 years of age with severe atopic dermatitis or moderate to severe asthma; and adults with uncontrolled chronic rhinosinusitis with nasal polyps, or with moderate-to-severe prurigo nodularis.
Please review the full Product Information before prescribing. Full Product Information can be accessed here.
â–¼ This medicinal product is subject to additional monitoring in Australia. This will allow quick identification of new safety information. Healthcare professionals are asked to report any suspected adverse events at www.tga.gov.au/reporting-problems
MAT-AU-2300941: April 2023